- Home
- PAI vs XOMAP Comparison
PAI vs XOMAP Comparison
Compare PAI & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAI
- XOMAP
- Stock Information
- Founded
- PAI 1973
- XOMAP N/A
- Country
- PAI United States
- XOMAP United States
- Employees
- PAI N/A
- XOMAP 13
- Industry
- PAI Trusts Except Educational Religious and Charitable
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- PAI Finance
- XOMAP Health Care
- Exchange
- PAI Nasdaq
- XOMAP Nasdaq
- Market Cap
- PAI N/A
- XOMAP N/A
- IPO Year
- PAI N/A
- XOMAP N/A
- Fundamental
- Price
- PAI $12.32
- XOMAP $25.30
- Analyst Decision
- PAI
- XOMAP
- Analyst Count
- PAI 0
- XOMAP 0
- Target Price
- PAI N/A
- XOMAP N/A
- AVG Volume (30 Days)
- PAI 25.0K
- XOMAP N/A
- Earning Date
- PAI 01-01-0001
- XOMAP N/A
- Dividend Yield
- PAI 4.78%
- XOMAP N/A
- EPS Growth
- PAI N/A
- XOMAP N/A
- EPS
- PAI N/A
- XOMAP N/A
- Revenue
- PAI N/A
- XOMAP N/A
- Revenue This Year
- PAI N/A
- XOMAP N/A
- Revenue Next Year
- PAI N/A
- XOMAP N/A
- P/E Ratio
- PAI N/A
- XOMAP N/A
- Revenue Growth
- PAI N/A
- XOMAP N/A
- 52 Week Low
- PAI $10.59
- XOMAP N/A
- 52 Week High
- PAI $12.63
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- PAI 55.25
- XOMAP 45.51
- Support Level
- PAI $12.27
- XOMAP $25.21
- Resistance Level
- PAI $12.54
- XOMAP $26.28
- Average True Range (ATR)
- PAI 0.21
- XOMAP 0.17
- MACD
- PAI 0.03
- XOMAP -0.04
- Stochastic Oscillator
- PAI 59.66
- XOMAP 31.78
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.